Executing Global Partnership (GP) projects in Sub-Saharan Africa and - - PowerPoint PPT Presentation

▶
executing global partnership gp projects in sub saharan
SMART_READER_LITE
LIVE PREVIEW

Executing Global Partnership (GP) projects in Sub-Saharan Africa and - - PowerPoint PPT Presentation

Sep 06, 2023 49 likes •272 views

Executing Global Partnership (GP) projects in Sub-Saharan Africa and Egypt Martin H. Groschup Head of Institute of Novel and Emerging Infectious Diseases at Friedrich-Loeffler-Institut Island of Riems, Germany Institute of Novel and Emerging

slide-1
SLIDE 1

Institute of Novel and Emerging Infectious Diseases

Martin H. Groschup Head of Institute of Novel and Emerging Infectious Diseases at Friedrich-Loeffler-Institut Island of Riems, Germany

Executing Global Partnership (GP) projects in Sub-Saharan Africa and Egypt

2nd OIE Global Conference on Biological Threat Reduction, Ottawa, Oct. 31st– Nov. 2nd,.2017

slide-2
SLIDE 2

Institute of Novel and Emerging Infectious Diseases

Sierra Leone Njala University, Department

  • f Animal

Science Mauritania Centre National de l'Élevage et de Recherches Vétérinaires (CNERV) Cameroon National Veterinary Laboratory (LANAVET) University Yaounde I Egypt Kafr el Sheik University Mansoura University

Prevalence and diagnostics of Ø Crimean-Congo hemorrhagic fever, Ø Rift valley fever and Ø zoonotic paramyxoviruses in

Mauri- tania Sierra Leone Came- roon Egypt

Kick off 2013

slide-3
SLIDE 3

Institute of Novel and Emerging Infectious Diseases

3

  • Two 3-year program terms (2013-2016 and 2017-2019) are part of

Germany's commitment to the G7 Global Partnership.

  • The program is based on the Biological Security Deliverables of the G7

Biosecurity Sub-Working Group (BSWG).

  • The program is funded and managed by the Federal Foreign Office.
  • Program Goals

– Reduce global biological security risks – Reinforce Germany’s contribution to global biosecurity – Strengthen Germany’s role in the Global Partnership group

slide-4
SLIDE 4

Institute of Novel and Emerging Infectious Diseases

Phase I (2013-2016, blue and red) Phase II (2017-2019, red)

+ regional: GIBACHT Academy

slide-5
SLIDE 5

Institute of Novel and Emerging Infectious Diseases

Bundeswehr Institute of Microbiology

Implementing Partners

slide-6
SLIDE 6

Institute of Novel and Emerging Infectious Diseases

6

Toolbox approach

The activities supported by the program are divided into six key areas with a large number of different modules. This methodological framework ensures a comprehensive contribution to global biosafety and allows tailor-made projects for each partner country.

slide-7
SLIDE 7

Institute of Novel and Emerging Infectious Diseases

Implementing the six key areas

7

Biosafety and Biosecurity:

Ensure safe and adequate working conditions in order to prevent accidents (biosafety). Establish security standards in laboratories to prevent theft / intentional misuse of dangerous agents (biosecurity). Implementation of biosafety/biosecurity in national legislations

Capacity Building:

Building the laboratory and personnel capacities to improve public health systems

Surveillance:

On-going systematic collection, analysis, evaluation and dissemination of data on infectious diseases for the purpose

  • f planning, implementation and evaluation of disease control measures.

Detection and Diagnostics:

Develop / establish pathogen detection and diagnostic assays in laboratories.

Networking:

Establishment national, international and intersectoral cooperation. Information about biological threats is actively shared with global public health community.

Awareness Raising:

For biosafety / biosecurity issues (incl. challenges to the health system) to design and implement risk mitigation strategies.

slide-8
SLIDE 8

Institute of Novel and Emerging Infectious Diseases

Interactions with top-level political authorities

v Meetings v Networking v Implementation of biosecurity agenda

Mai Moussa Abari, FAO Representative to Cameroon

  • Dr. Taiga, Minister of Livestock, Fisheries

and Animal-Industries, Cameroon

  • Dr. Lemrabott
  • Dr. Winter

CVO Mauritania German Ambassador

slide-9
SLIDE 9

Institute of Novel and Emerging Infectious Diseases

Training of African experts at FLI in 2013-2017

24 participants from Ø Sierra Leone (6) Ø Cameroon (7) Ø DR Congo (4) Ø Mauritania (1) Ø Egypt (6) Training (2-3 weeks) included ELISA, IFA and PCR for CCHFV and RVFV, aspects of biosafety and biosecurity Training success was evaluated by blinded internal ring trials with participants

Fifa World Cup 2014

slide-10
SLIDE 10

Institute of Novel and Emerging Infectious Diseases

Nine workshops in African partner laboratories 2013-2017

10-days Workshop Outbreak-Management, Diagnostics, Biosafety Training of 4 scientists/ lab technicians / students Mauritania, 2013 Mauritania, 2013 10-days Workshop Diagnostic, Biosafety, Organization of Laboratory Training of 5 scientists/ lab technicians / students Sierra Leone, 2014 14-days Workshop Diagnostic, Organization of Laboratory + Infrastructure Training of 12 scientists/ lab technicians / students DR Congo, 2014 10-days Workshop Diagnostic, Biosafety, Organization Infrastructure Training of 12 scientists/ lab technicians / students Cameroon, 2015

slide-11
SLIDE 11

Institute of Novel and Emerging Infectious Diseases

slide-12
SLIDE 12

Institute of Novel and Emerging Infectious Diseases

Key question: How to keep the v infrastructures functional and v personnel motivated and trained

  • ver time?

à Goal is to achieve long- term sustainability

slide-13
SLIDE 13

Institute of Novel and Emerging Infectious Diseases

Motivations: 1) Donor country 2) Donor country partnering institution 3) African partner countries 4) African partnering institutions

slide-14
SLIDE 14

Institute of Novel and Emerging Infectious Diseases

Motivations: 1) Donor country Ø Striving for the Biological Security Deliverables 2) Donor country partnering institution 3) African partner countries Ø Striving for the Biological Security Deliverables Ø Capacity building - legal framework for biosecurity

  • functional laboratories
  • training of diagnosticians / scientists

4) African partnering institutions

slide-15
SLIDE 15

Institute of Novel and Emerging Infectious Diseases

Motivations: 1) Donor country Ø Striving for the Biological Security Deliverables 2) Donor country partnering institution 3) African partner countries Ø Striving for the Biological Security Deliverables Ø Capacity building - public health system

  • livestock industry
  • biodiversity / tourism

4) African partnering institutions

slide-16
SLIDE 16

Institute of Novel and Emerging Infectious Diseases

Motivations: 1) Donor country 2) Donor country partnering institution 3) African partner countries 4) African partnering institutions Ø Infrastructure and workforce development Ø Network building Ø Research interests

slide-17
SLIDE 17

Institute of Novel and Emerging Infectious Diseases

Motivations: 1) Donor country 2) Donor country partnering institution Ø International animal health mission Ø Research interests 3) African partner countries 4) African partnering institutions Ø Infrastructure and workforce development Ø Network building Ø Research interests

slide-18
SLIDE 18

Institute of Novel and Emerging Infectious Diseases

Common research interests of FLI and African partners

Preparedness for the emergence of novel or already known biothreat pathogens

  • Virus discovery and phylogeny studies
  • Virus isolation
  • Diagnostic method development (qPCR, serology) and assay validation
  • Surveillance and molecular epidemiology
  • In vivo pathogenesis studies under BSL3/4 conditions
  • Development of veterinary and public health protection strategies

(management, vaccination)

à Access to biological samples Publications together with African partners

slide-19
SLIDE 19

Institute of Novel and Emerging Infectious Diseases

Major scientific achievements

  • Development of a battery of new molecular and serological assays for

the diagnosis of RVFV and CCHFV infections

  • Better understanding of prevalence of RVFV and CCHFV infections in

animals for many African countries

  • Detection of target pathogens in risk areas
  • Detection of off-target hemorrhagic fever viruses (e.g. NgariV)
  • Insight into the role of ruminants (cattle, goats, sheep, camels etc.)

as reservoir hosts and of arthropods as vectors for these bunyaviral hemorrhagic fever viruses (studies ongoing)

slide-20
SLIDE 20

Institute of Novel and Emerging Infectious Diseases

1. Schuster I., Mertens M, Mrenoski S, Staubach C, Mertens C, Bruning F, Wernike K, Hechinger S, Berxholi K, Mitrov D, Groschup MH. Sheep and goats as indicator animals for the circulation of CCHFV in the environment. Exp Appl Acarol (2016) 2. Schuster I, Mertens M, Kollner B, Korytar T, Keller M, Hammerschmidt B, Muller T, Tordo N, Marianneau P, Mroz C, Rissmann M, Stroh E, Dahnert L, Hammerschmidt F, Ulrich RG, Groschup MH. A competitive ELISA for species-independent detection of Crimean-Congo hemorrhagic fever virus specific

  • antibodies. Antiviral Res. (2016)

3. Sas MA, Vina-Rodriguez A, Mertens M, Eiden M, Emmerich P, Chantoutis SC, Mirazimi A, Groschup MH Universal Multiplex Real-Time PCR for all CCHFV Genotypes, submitted 4. López-Gil E, Lorenzo G, Hevia E, Borrego B, Eiden M, Groschup M, Gilbert SC, Brun A. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2309. doi: 10.1371/journal.pntd.0002309. Print 2013. 5. Jäckel S, Eiden M, Balkema-Buschmann A, Ziller M, van Vuren PJ, Paweska JT, Groschup MH. A novel indirect ELISA based on glycoprotein Gn for the detection of IgG antibodies against Rift Valley fever virus in small ruminants. Res Vet Sci.2013 Oct;95(2):725-30. doi: 10.1016/j.rvsc.2013.04.015. 6. Kortekaas J, Kant J, Vloet R, Cêtre-Sossah C, Marianneau P, Lacote S, Banyard AC, Jeffries C, Eiden M, Groschup M, Jäckel S, Hevia E, Brun A. European ring trial to evaluate ELISAs for the diagnosis of infection with Rift Valley fever virus. J Virol Methods. 2013 Jan;187(1):177-81. doi: 10.1016/j.jviromet.2012.09.016. Epub 2012 Sep 26. PubMed PMID: 23022325. 7. Rissmann M, Ulrich R, Schröder C, Hammerschmidt B, Hanke D, Mroz C, Groschup MH, Eiden M. Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine. Vaccine. 2017 Jan 23;35(4):655-662. doi: 10.1016/j.vaccine.2016.12.003. 8. Rissmann M, Eiden M, Wade A, Poueme R, Abdoulkadiri S, Unger H, Ziegler U,Homeier T, Groschup MH. Evidence for enzootic circulation of Rift Valley fever virus among livestock in Cameroon. Acta Trop. 2017 Apr 17;172:7-13. doi:10.1016/j.actatropica.2017.04.001. 9. Mroz C, Gwida M, El-Ashker M, El-Diasty M, El-Beskawy M, Ziegler U, Eiden M, Groschup MH. Seroprevalence of Rift Valley fever virus in livestock during inter-epidemic period in Egypt, 2014/15. BMC Vet Res. 2017 Apr 5;13(1):87. doi: 10.1186/s12917-017-0993-8.

  • 10. Mroz C, Gwida M, El-Ashker M, Ziegler U, Homeier-Bachmann T, Eiden M, Groschup MH. Rift Valley fever virus infections in Egyptian cattle and their
  • prevention. Transbound Emerg Dis. 2017 Jan 24. doi: 10.1111/tbed.12616.
  • 11. Rissmann M, Eiden M, El Mamy BO, Isselmou K, Doumbia B, Ziegler U,Homeier-Bachmann T, Yahya B, Groschup MH. Serological and genomic evidence of

Rift Valley fever virus during inter-epidemic periods in Mauritania. Epidemiol Infect. 2017 Apr;145(5):1058-1068. doi: 10.1017/S0950268816003022.

  • 12. Eiden M, Vina-Rodriguez A, El Mamy BO, Isselmou K, Ziegler U, Höper D, Jäckel S, Balkema-Buschmann A, Unger H, Doumbia B, Groschup MH. Ngari virus

in goats during Rift Valley fever outbreak, Mauritania, 2010. Emerg Infect Dis. 2014 Dec;20(12):2174-6. doi: 10.3201/eid2012.140787.

  • 13. Jäckel S, Eiden M, El Mamy BO, Isselmou K, Vina-Rodriguez A, Doumbia B, Groschup MH. Molecular and serological studies on the Rift Valley fever
  • utbreak in Mauritania in 2010. Transbound Emerg Dis. 2013 Nov;60 Suppl 2:31-9. doi: 10.1111/tbed.12142.
  • 14. Rissmann M, Eiden M, Wade A, Poueme R, Abdoulkadiri S, Unger H, Ziegler U,Homeier T, Groschup MH. Evidence for enzootic circulation of Rift Valley

fevervirus among livestock in Cameroon. Acta Trop. 2017 Apr 17;172:7-13. doi:10.1016/j.actatropica.2017.04.001.

  • 15. Mroz C, Gwida M, El-Ashker M, El-Diasty M, El-Beskawy M, Ziegler U, Eiden M, Groschup MH. Seroprevalence of Rift Valley fever virus in livestock during

inter-epidemic period in Egypt, 2014/15. BMC Vet Res. 2017 Apr 5;13(1):87. doi: 10.1186/s12917-017-0993-8.

  • 16. Mroz C, Gwida M, El-Ashker M, Ziegler U, Homeier-Bachmann T, Eiden M, Groschup MH. Rift Valley fever virus infections in Egyptian cattle and their
  • prevention. Transbound Emerg Dis. 2017 Jan 24. doi: 10.1111/tbed.12616.
  • 17. Rissmann M, Eiden M, El Mamy BO, Isselmou K, Doumbia B, Ziegler U,Homeier-Bachmann T, Yahya B, Groschup MH. Serological and genomic evidence of

Rift Valley fever virus during inter-epidemic periods in Mauritania. Epidemiol Infect. 2017 Apr;145(5):1058-1068. doi: 10.1017/S0950268816003022.

  • 18. Eiden M, Vina-Rodriguez A, El Mamy BO, Isselmou K, Ziegler U, Höper D, Jäckel S, Balkema-Buschmann A, Unger H, Doumbia B, Groschup MH. Ngari virus

in goats during Rift Valley fever outbreak, Mauritania, 2010. Emerg Infect Dis. 2014 Dec;20(12):2174-6. doi: 10.3201/eid2012.140787.

  • 19. Jäckel S, Eiden M, El Mamy BO, Isselmou K, Vina-Rodriguez A, Doumbia B, Groschup MH. Molecular and serological studies on the Rift Valley fever
  • utbreak in Mauritania in 2010. Transbound Emerg Dis. 2013 Nov;60 Suppl 2:31-9. doi: 10.1111/tbed.12142.
  • 20. Maiga O, Sas MA, Rosenke K, Kamissoko B, Mertens M, Sogoba N, Traore A, Sangare M, Niang M, Schwan TG, Maiga HM, Traore SF, Feldmann H,

Safronetz D, Groschup MH. Serosurvey of Crimean-Congo Hemorrhagic Fever Virus in Cattle, Mali, West Africa. Am J Trop Med Hyg. 2017 Jun;96(6):1341-

  • 1345. doi: 10.4269/ajtmh.16-0818.
  • 21. Sas MA, Mertens M, Kadiat JG, Schuster I, Pongombo CPS, Maloba AGK, Groschup MH. Serosurvey for Crimean-Congo hemorrhagic fever virus infections

in ruminants in Katanga province, Democratic Republic of the Congo. Ticks Tick Borne Dis. 2017 Oct;8(6):858-861. doi: 10.1016/j.ttbdis.2017.07.001.

  • 22. Sas MA, Mertens M, Isselmou E, Reimer N, El Mamy BO, Doumbia B, Groschup MH. Crimean-Congo Hemorrhagic Fever Virus-Specific Antibody Detection

in Cattle in Mauritania. Vector Borne Zoonotic Dis. 2017 Aug;17(8):582-587. doi: 10.1089/vbz.2016.2084.

In addition to implementing biosecurity agenda Project related publications 2013-17 majority together with African scientists

slide-21
SLIDE 21

Institute of Novel and Emerging Infectious Diseases

FLI approach to sustain biosecurity program effects

Capacity building:

Ø Assistance in setting up functional laboratory infrastructures ü laboratory construction work ü provision of new equipment or by bringing abandoned/unused high-tech equipment from previous capacity building projects into operation Ø technical training of personnel (scientists and technicians)

Identification and support of the most capable and trustful scientists (HQPs)

à Helping HQP to become scientific leaders and personal role models for the future

à major investment should go into people Inspiring a culture of scientific collaboration and research

ü long-term involvement rather than short-term/limited project activities ü introduction to international (NS/SS) research community ü scientific collaboration projects run by African scientists

à more scientific research à Nucleus for follow up collaboration projects in- and outside of GP program à Continuation of activities and of biosecurity agenda / reduces brain drain

slide-22
SLIDE 22

Institute of Novel and Emerging Infectious Diseases

Contributions

FLI Marc Mertens Miriam Andrada Sas Martin Eiden Melanie Rissmann Ute Ziegler Ariel Vina Rodriguez Isolde Schuster Martin H. Groschup IAEA Vienna Hermann Unger NIH Montana Heinz Feldmann David Safronetz GIZ Joachim von Bonin Mali (Int. Center of Excellence in Research) Ousman Maiga

Collaboration partners

Mauritania (CNERV) Bezeid Ould Elmamy Baba Doumbia Barry Yahya Sierra Leone (Njala University) Saidu Kanu Roland Suluku Cameroon (LANAVET & University Yaounde 1) Abel Wade Samuel Abah Wilfred Mbacham DR Congo (University Lubumbashi & LVL) Celestin Pongombo Alois Maloba Egypt (Mansoura & Kafrelsheik University) Mayada Gwida

  • Dr. Maged El-Ashker

Many thanks for your attention